76 / 1851
Residual Disease Trials
•
Good
:
–
Tissue available
–
Resistant tumors
–
High risk population
•
Bad
:
–
Adjuvant-size trial
–
Cannot assess response
(event = relapse)
New Diagnosis
Post-Rx
residual
disease
Neoadjuvant Rx
Investigational
Drug Rx
Relapse
Example: PENELOPE – palbociclib in residual ER+ disease